Transcriptomics Market Size, Share and Global Trend By Technology (Polymerase Chain Reaction (PCR), Microarray, Next-Generation Sequencing (NGS)), By Application (Drug Discovery, Clinical Diagnostics, Toxicogenomics), By End-User (Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies) and Regional Forecast, 2024-2032

In April 2017, NuGEN Technologies, Inc. launched Trio RNA-Seq, which is predominantly suited for low abundance transcripts applications. Transcriptomic is the study of the complete set of RNAs (transcriptome) encoded by the genome of an organism at a specific time or specific cell or under a specific set of conditions. Transcriptomics includes the consideration and assortment of transcriptomes and has diverse applications, including applications in molecular genetics.

Transcriptomics techniques include DNA microarrays and next-generation sequencing technologies called RNA-Seq. As the demand for transcriptomics is increasing, new players are entering into the market. For instance, in April 2017, Seven Bridges, a biomedical data analysis company announced a financial investment in Spatial Transcriptomics AB, a life science start-up, which is developing innovative technology to analyze tissue samples in two dimensions.

Increasing demand for personalized medicines and rapid improvements in healthcare infrastructures are anticipated to fuel the growth of the drug discovery and research, which will eventually drive the growth of the global transcriptomic market during the forecast period. An increasing number of biopharmaceutical companies and rising expenditure on research and development is projected to boost the growth of the global transcriptomics market by 2026.

However, the lack of skilled professionals in emerging nations is expected to hamper the growth of the global transcriptomics market during the forecast period.

Key Players Covered

Some of the major companies operating in the global transcriptomics market are QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, GE Healthcare Dharmacon Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Fluidigm Corporation, Promega Corporation, and others.

SEGMENTATION

Among the segmentation, pharmaceutical companies among end-user segment are projected to register comparatively higher share owing to increasing drug manufacturing.

Key Insights

• Technological advancements in transcriptomics


• New product introduction


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

Based on the region, the global transcriptomics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among the region, North America is expected to dominate the global transcriptomics market owing to increased demand for the personalized medicines, growing incidence of chronic disorders such as cancer and others, and high investment in the research and development of the transcriptomics technologies. Asia Pacific is expected to grow at a significant CAGR, during the forecast period due to the increasing number of pharmaceutical and biotechnology companies in the region, leading to higher demand for transcriptomics technologies, combined with increasing investments in R&D and drug development in the Asia Pacific.

Key Industry Developments

• In February 2019, Caris Life Sciences launched an advanced gene profiling product, MI Transcriptome which enables Whole Transcriptome Sequencing (WTS). The newly developed technology has the capability to provide in detail RNA sequencing analysis.
• In February 2019, Lexogen launched of CORALL Total RNA-Seq Library Prep Kit. This newly launched kit can be utilized in transcriptome analysis.
• In December 2018, 10x Genomics acquired Spatial Transcriptomics, a potential player in spatial genomics.